Summary
Gilead Sciences, Inc. (GILD) has officially completed its acquisition of CV Therapeutics, Inc. through a cash tender offer and subsequent merger. This transaction, finalized on April 15, 2009, saw all outstanding shares of CV Therapeutics' common stock acquired for $20.00 per share, a price consistent with the tender offer. The merger, completed on April 17, 2009, solidified CV Therapeutics as a wholly-owned subsidiary of Gilead. This 8-K filing primarily serves to confirm the closing of this acquisition. Importantly, Gilead has stated that the acquired business is not considered significant enough to require the filing of financial statements or pro forma information in this report. Investors should note that this event marks a significant expansion for Gilead, likely aimed at bolstering its product pipeline and market presence.
Key Highlights
- 1Gilead Sciences, Inc. completed the acquisition of CV Therapeutics, Inc. via a cash tender offer and subsequent merger.
- 2The acquisition closed on April 15, 2009, with all validly tendered shares of CV Therapeutics common stock accepted for payment.
- 3The merger was completed on April 17, 2009, making CV Therapeutics a wholly-owned subsidiary of Gilead.
- 4The purchase price for CV Therapeutics common stock was $20.00 in cash per share.
- 5Gilead funded the acquisition with its own resources.
- 6The acquired business was not deemed significant enough to require the filing of financial statements or pro forma information with this 8-K.
- 7The filing includes press releases from April 15 and April 17, 2009, announcing the offer results and merger completion.